Getinge AB (publ) (GNGBF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Getinge AB (publ) (GNGBF) trades at $20.05 with AI Score 50/100 (Grade B). Getinge AB (publ) provides equipment and solutions for healthcare facilities globally. Market cap: $5.10B, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for GNGBF: GNGBF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GNGBF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
GNGBF: the 1 perspectives are evenly split.
How is this calculated? →Getinge AB (publ) (GNGBF) Healthcare & Pipeline Overview
Getinge AB (publ) is a global provider of medical technology, offering solutions for operating rooms, intensive care units, and sterilization departments. With a diverse portfolio spanning acute care, life science, and surgical workflows, Getinge serves healthcare providers across the Americas, Europe, the Middle East, Africa, and the Asia Pacific, maintaining a significant presence in the medical device industry.
What Is the Investment Thesis for GNGBF?
Getinge AB (publ) presents a compelling investment case based on its established market position and diverse product portfolio within the healthcare sector. With a current P/E ratio of 23.0 and a dividend yield of 2.43%, the company demonstrates financial stability. Growth catalysts include expanding its presence in emerging markets and continuous innovation in its core product segments. The company's focus on acute care therapies, life science solutions, and surgical workflows positions it to capitalize on increasing healthcare spending and technological advancements. However, potential risks include regulatory hurdles and competition from other medical device manufacturers. The company's gross margin of 45.9% and profit margin of 6.5% indicate a solid foundation for future growth.
Based on FMP financials and quantitative analysis
GNGBF Key Highlights
- Market Cap of $5.10B reflects Getinge's significant presence in the medical device industry.
- P/E Ratio of 23.0 indicates a valuation in line with industry peers.
- Gross Margin of 45.9% demonstrates efficient cost management and pricing strategies.
- Dividend Yield of 2.43% provides a steady return for investors.
- Beta of 0.88 suggests lower volatility compared to the overall market.
Who Are GNGBF's Competitors?
GNGBF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADDLF AddLife AB (publ) | $15.75 | +0.00% | $1.85B | 45 |
| AHICF Asahi Intecc Co., Ltd. | $22.60 | +5.58% | $6.00B | 58 |
| AKBLF ALK-Abelló A/S | $40.65 | +0.00% | $8.18B | 55 |
| AMBBY Ambu A/S | $9.70 | +0.00% | $2.58B | 47 |
| CLCGY Clicks Group Limited | $29.10 | +1.78% | $3.40B | 46 |
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GNGBF's Key Strengths?
- Strong global presence and distribution network.
- Diverse product portfolio across multiple healthcare segments.
- Established brand reputation and customer loyalty.
- Focus on innovation and technological advancements.
What Are GNGBF's Weaknesses?
- Exposure to regulatory risks and compliance requirements.
- Dependence on healthcare spending and economic conditions.
- Competition from larger medical device manufacturers.
- Potential for product recalls and liability claims.
What Could Drive GNGBF Stock Higher?
- Expansion of product portfolio through research and development.
- Increasing demand for healthcare solutions in emerging markets.
- Strategic partnerships and acquisitions to expand market reach.
- Potential regulatory approvals for new medical devices.
- Launch of innovative surgical workflow solutions in Q4 2026.
What Are the Key Risks for GNGBF?
- Changes in healthcare regulations and reimbursement policies.
- Economic downturns and reduced healthcare spending.
- Increasing competition from established and emerging players.
- Product recalls and liability claims.
- Fluctuations in currency exchange rates.
What Are the Growth Opportunities for GNGBF?
- Growth opportunity 1: Expansion in Emerging Markets: Getinge has the opportunity to expand its presence in emerging markets, particularly in Asia Pacific and Latin America, where healthcare spending is rapidly increasing. By tailoring its product offerings to meet the specific needs of these markets, Getinge can capitalize on the growing demand for advanced medical technologies. This expansion could contribute significantly to revenue growth over the next 3-5 years, with the global medical device market projected to reach $600 billion by 2025.
- Growth opportunity 2: Innovation in Surgical Workflows: Getinge can further enhance its surgical workflow solutions by integrating advanced technologies such as robotics and artificial intelligence. This would improve the efficiency and precision of surgical procedures, leading to better patient outcomes and increased demand for Getinge's products. The market for surgical robotics is expected to reach $12.6 billion by 2025, presenting a substantial growth opportunity for Getinge.
- Growth opportunity 3: Focus on Infection Control Solutions: With increasing concerns about hospital-acquired infections, Getinge can capitalize on the growing demand for advanced infection control solutions. By developing innovative sterilization and disinfection technologies, Getinge can help healthcare providers reduce the risk of infections and improve patient safety. The global infection control market is projected to reach $25 billion by 2027, offering a significant growth opportunity for Getinge.
- Growth opportunity 4: Strengthening the Life Science Segment: Getinge's Life Science segment can benefit from the increasing demand for bioprocessing solutions in the pharmaceutical and biotechnology industries. By expanding its portfolio of bioreactors, bioprocess control systems, and bioprocess software, Getinge can support the development and manufacturing of new drugs and therapies. The global bioprocessing market is expected to reach $35 billion by 2028, presenting a substantial growth opportunity for Getinge.
- Growth opportunity 5: Strategic Acquisitions and Partnerships: Getinge can pursue strategic acquisitions and partnerships to expand its product portfolio and geographic reach. By acquiring companies with complementary technologies or entering into partnerships with leading healthcare providers, Getinge can strengthen its competitive position and accelerate its growth. This strategy can provide access to new markets and technologies, enhancing Getinge's long-term growth prospects.
What Opportunities Does GNGBF Have?
- Expansion in emerging markets with growing healthcare demand.
- Development of new products and solutions to address unmet needs.
- Strategic acquisitions and partnerships to expand market reach.
- Integration of advanced technologies such as AI and robotics.
What Threats Does GNGBF Face?
- Increasing competition from established and emerging players.
- Changes in healthcare regulations and reimbursement policies.
- Economic downturns and reduced healthcare spending.
- Disruptive technologies and new market entrants.
What Are GNGBF's Competitive Advantages?
- Established brand reputation in the medical device industry.
- Diverse product portfolio across multiple healthcare segments.
- Global distribution network providing access to a wide customer base.
- Strong focus on innovation and technological advancements.
What Does GNGBF Do?
Founded in 1904 and headquartered in Gothenburg, Sweden, Getinge AB (publ) has evolved into a leading global provider of medical technology. The company operates through three primary segments: Acute Care Therapies, Life Science, and Surgical Workflows. The Acute Care Therapies segment offers products and solutions for intensive care units, including advanced monitoring systems, anesthesia machines, and mechanical ventilation products. The Life Science segment provides solutions for sterile transfer, bioprocess control, and sterilization within the pharmaceutical and biotechnology industries. The Surgical Workflows segment focuses on optimizing operating room efficiency with products such as operating tables, surgical lights, and integrated OR management systems. Getinge's comprehensive portfolio includes sterile transfer systems, closure processing systems, washers, isolators, sterilizers, logistic automation solutions, bioreactors, bioprocess control systems, bioprocess software, biobundles, bioprocess analytics, and perfusion systems. The company also offers practice-oriented monitoring systems and disposables, anesthesia machines, beating heart stabilizers and positioners, and a range of surgical solutions. Getinge distributes its products through a network of proprietary sales companies, agents, and distributors across the Americas, Europe, the Middle East, Africa, and the Asia Pacific, serving a global customer base.
What Products and Services Does GNGBF Offer?
- Provides equipment for operating rooms.
- Offers solutions for intensive-care units.
- Supplies sterilization departments with necessary equipment.
- Develops and markets sterile transfer systems.
- Creates bioprocess control systems for the life science industry.
- Offers surgical assist systems and related solutions.
- Provides solutions for vascular and cardiothoracic surgery.
How Does GNGBF Make Money?
- Develops and manufactures medical devices and equipment.
- Sells products directly through proprietary sales companies.
- Utilizes agents and distributors for broader market reach.
- Provides after-sales service and support for its products.
What Industry Does GNGBF Operate In?
Getinge AB (publ) operates within the global medical device industry, a sector characterized by continuous innovation and increasing demand driven by an aging population and rising healthcare expenditures. The industry is highly competitive, with key players focusing on technological advancements and geographic expansion. Getinge's focus on acute care therapies, life science solutions, and surgical workflows aligns with major market trends, including the growing demand for minimally invasive surgical procedures and advanced sterilization technologies. The company's global presence allows it to capitalize on growth opportunities in both developed and emerging markets.
Who Are GNGBF's Key Customers?
- Hospitals and healthcare facilities.
- Pharmaceutical and biotechnology companies.
- Research institutions.
- Sterilization departments.
Company Profile
Getinge AB (publ) operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Gothenburg, SE. The company is led by CEO Mattias Perjos. GNGBF has traded publicly since 2011.
F-Score 7/9Financial Health
Getinge AB (publ)'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 2.53 places it in the grey zone, a middle ground that warrants monitoring.
ROE 8%Key Financial Metrics
Return on equity for Getinge AB (publ) stands at 8.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 4.1%, showing how much profit it generates from its asset base. GNGBF trades at a trailing price-to-earnings ratio of 23.02, roughly in line with the Healthcare sector average of ~23x. Its free cash flow yield is 6.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.35 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.3%, the inverse of the P/E and a quick read on earnings relative to price.
GNGBF Valuation & Market Position
With a $5.10B market cap, Getinge AB (publ) sits in the mid-cap segment of the market. Relative to its peer group, GNGBF's quantitative score of 50/100 is roughly in line with the peer average of 50/100.
FY2026 estForward Outlook
Wall Street analysts project Getinge AB (publ) revenue of about $34.78B for fiscal 2026, with EPS near $11.53. The estimate reflects 10 contributing analysts.
GNGBF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Strong global presence and distribution network.
- Diverse product portfolio across multiple healthcare segments.
- Established brand reputation and customer loyalty.
- Focus on innovation and technological advancements.
Bear Case
- Exposure to regulatory risks and compliance requirements.
- Dependence on healthcare spending and economic conditions.
- Competition from larger medical device manufacturers.
- Potential for product recalls and liability claims.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
GNGBF Latest News
-
Getinge Launches Vasoview Hemopro 3, Advancing Endoscopic Vessel Harvesting
Yahoo! Finance: GNGBF News · Jun 2, 2026
-
Is Avantor (AVTR) Elevating Quality To A Strategic Edge With Its New Regulatory Chief?
Yahoo! Finance: GNGBF News · Jun 1, 2026
-
Getinge's subsidiary Maquet Cardiovascular receives adverse jury trial verdict in patent infringement dispute with Abiomed in the U.S.
Yahoo! Finance: GNGBF News · May 28, 2026
GNGBF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GNGBF.
Price Targets
Wall Street price target analysis for GNGBF.
GNGBF MoonshotScore
What does this score mean?
The MoonshotScore rates GNGBF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Getinge Launches Vasoview Hemopro 3, Advancing Endoscopic Vessel Harvesting
Is Avantor (AVTR) Elevating Quality To A Strategic Edge With Its New Regulatory Chief?
Getinge's subsidiary Maquet Cardiovascular receives adverse jury trial verdict in patent infringement dispute with Abiomed in the U.S.
Leadership: Mattias Perjos
President & CEO
Mattias Perjos serves as the President and CEO of Getinge AB (publ). His career includes leadership roles in various technology and healthcare companies. He has a strong background in strategic management and business development. Prior to joining Getinge, Perjos held key positions at Coesia Group and Sandvik, gaining experience in international business and operational excellence. His expertise spans across multiple industries, providing him with a diverse perspective on business challenges and opportunities.
Track Record: Under Mattias Perjos' leadership, Getinge has focused on strengthening its core business segments and expanding its global presence. He has overseen the implementation of strategic initiatives aimed at improving operational efficiency and driving innovation. Key achievements include the launch of new products and solutions, as well as the expansion of Getinge's service offerings. Perjos has also emphasized sustainability and corporate responsibility, aligning Getinge's business practices with environmental and social goals.
GNGBF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Getinge AB (publ) may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial disclosure and may not be subject to the same level of regulatory scrutiny as those listed on major exchanges like the NYSE or NASDAQ. This tier is often populated by shell companies, companies in bankruptcy, or those unwilling or unable to meet higher listing standards. Investors should exercise significant caution when considering investments in OTC Other securities due to the increased risks associated with limited information and potential for fraud or manipulation.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Financial Disclosure: The lack of readily available and reliable financial information increases the risk of investing in GNGBF.
- Low Liquidity: The low trading volume and wide bid-ask spread can make it difficult to buy or sell shares at a fair price.
- Potential for Fraud or Manipulation: The OTC market is more susceptible to fraudulent schemes and market manipulation due to the lower regulatory oversight.
- Delisting Risk: GNGBF could be delisted from the OTC market if it fails to meet the minimum listing requirements or comply with regulatory standards.
- Information Asymmetry: The limited information available to investors can create an uneven playing field, where insiders have an advantage over outside investors.
- Verify the company's financial statements and audit reports.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Review the company's filings with regulatory agencies.
- Consult with a qualified financial advisor.
- Understand the risks associated with investing in OTC stocks.
- Check for any legal or regulatory actions against the company.
- Established Operations: Getinge AB (publ) has been in operation since 1904, indicating a long-standing presence in the medical device industry.
- Global Presence: The company has a global distribution network and serves customers in multiple regions.
- Diverse Product Portfolio: Getinge offers a wide range of products and solutions across various healthcare segments.
- Publicly Traded: While traded on the OTC market, the company is a publicly traded entity, subject to some level of regulatory oversight.
Common Questions About GNGBF (Healthcare)
What does Getinge AB (publ) do?
Getinge AB (publ) is a global provider of medical technology focused on solutions for operating rooms, intensive care units, and sterilization departments. The company operates through three segments: Acute Care Therapies, Life Science, and Surgical Workflows. These segments offer a range of products, including advanced monitoring systems, anesthesia machines, sterilization equipment, and surgical assist systems. Getinge's products are used by hospitals, pharmaceutical companies, and research institutions worldwide, contributing to improved patient outcomes and efficient healthcare operations. The company's business model involves developing, manufacturing, and distributing its products through a network of proprietary sales companies, agents, and distributors.
What do analysts say about GNGBF stock?
Analyst coverage of GNGBF is limited due to its OTC listing. However, considering Getinge's financial performance and market position, analysts generally view the company as a stable player in the medical device industry. Key valuation metrics, such as the P/E ratio of 23.0, suggest a valuation in line with industry peers. Growth considerations include the company's expansion in emerging markets and its focus on innovation. Investors should conduct their own due diligence and consider their individual risk tolerance before making any investment decisions.
What are the main risks for GNGBF?
Getinge AB (publ) faces several risks inherent to the medical device industry. These include regulatory risks associated with obtaining approvals for new products and complying with existing regulations. Economic downturns and reduced healthcare spending can also negatively impact the company's financial performance. Increasing competition from established and emerging players poses a threat to Getinge's market share. Product recalls and liability claims can result in significant financial losses and reputational damage. Additionally, fluctuations in currency exchange rates can affect the company's profitability due to its global operations.
How does Getinge AB (publ) navigate regulatory approval processes?
Getinge AB (publ) navigates regulatory approval processes by maintaining a dedicated regulatory affairs team that monitors and ensures compliance with relevant regulations in each market where its products are sold. The company focuses on adhering to stringent quality standards and conducting thorough clinical trials to support its product submissions. Getinge works closely with regulatory agencies such as the FDA in the United States and the EMA in Europe to ensure its products meet the required safety and efficacy standards. The company's track record includes successful approvals for a range of medical devices and solutions, demonstrating its commitment to regulatory compliance.
What are the key growth opportunities for GNGBF in healthcare?
Getinge AB (publ) has several key growth opportunities within the healthcare sector. These include expanding its presence in emerging markets, particularly in Asia Pacific and Latin America, where healthcare spending is rapidly increasing. The company can also capitalize on the growing demand for minimally invasive surgical procedures by developing innovative surgical workflow solutions. Furthermore, Getinge can benefit from the increasing focus on infection control by offering advanced sterilization and disinfection technologies. The company's expansion into new therapeutic areas and healthcare segments can also drive growth and enhance its market position.
What are the key factors to evaluate for GNGBF?
Getinge AB (publ) (GNGBF) holds an AI score of 50/100 (moderate). P/E: 23.0x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does GNGBF data refresh on this page?
GNGBF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven GNGBF's recent stock price performance?
Getinge AB (publ) (GNGBF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong global presence and distribution network. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending may provide further insights.
- OTC market data may have limited accuracy.